volume 3, issue 10, P1430 2017
DOI: 10.1001/jamaoncol.2017.0737
View full text
|
|
Share
David Cheng, Kyongsun Pak, Lee-Jen Wei

Abstract: To the Editor Siu and colleagues 1 conducted the largest clinical trial to date to assess accelerated-fractionation radiotherapy (AFX) plus panitumumab compared with standardfractionation radiotherapy (SFX) plus cisplatin. The study was designed for a superiority analysis to detect a difference in the progression-free survival (PFS) that corresponds to a hazard ratio (HR) of 0.70, requiring a total of 246 events and 320 patients to achieve appropriate statistical power. If superiority was not demonstrated, the…

expand abstract